









市场行情
/
股票
/
nasdaq-capr
/

Capricor Therapeutics Inc

CAPR

29.680USD

+0.780+2.70%

收盘 12/24, 13:00（美东）报价延迟15分钟

1.36B总市值

亏损市盈率 TTM



Capricor Therapeutics Inc

29.680

+0.780+2.70%

概览公司财务分析

概览

公司

财务

分析

关于 Capricor Therapeutics Inc 公司

Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.

Capricor Therapeutics Inc简介



公司代码CAPR

公司名称Capricor Therapeutics Inc

上市日期Jun 04, 2002

CEOMarban (Linda)

员工数量160

证券类型Ordinary Share

年结日Jun 04

公司地址10865 Road to the Cure

城市SAN DIEGO

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编92121

电话13103583200

网址https://capricor.com/

公司代码CAPR

上市日期Jun 04, 2002

CEOMarban (Linda)

Capricor Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Linda Marban, Ph.D.

President, Chief Executive Officer, Director

212.02K

+6.26%

Mr. David B. Musket

Independent Director

88.79K

Mr. Anthony Bergmann

Chief Financial Officer

8.22K

+43.68%

Dr. Michael Binks, M.D.

Chief Medical Officer

Dr. Frank I. Litvack, M.D.

Executive Chairman of the Board

Mr. George W. Dunbar, Jr.

Independent Director

Dr. Paul Auwaerter, M.D.

Independent Director

Ms. Karimah Es Sabar

Independent Director

Ms. Karen G. Krasney, J.D.

Executive Vice President, General Counsel

Dr. Philip J. (Phil) Gotwals, Ph.D.

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Linda Marban, Ph.D.

President, Chief Executive Officer, Director

212.02K

+6.26%

Mr. David B. Musket

Independent Director

88.79K

Mr. Anthony Bergmann

Chief Financial Officer

8.22K

+43.68%

Dr. Michael Binks, M.D.

Chief Medical Officer

Dr. Frank I. Litvack, M.D.

Executive Chairman of the Board

Mr. George W. Dunbar, Jr.

Independent Director

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

Nippon Shinyaku Co Ltd

15.51%

BlackRock Institutional Trust Company, N.A.

5.82%

The Vanguard Group, Inc.

4.83%

Geode Capital Management, L.L.C.

2.10%

State Street Investment Management (US)

1.75%

其他

69.99%

持股股东

占比

Nippon Shinyaku Co Ltd

15.51%

BlackRock Institutional Trust Company, N.A.

5.82%

The Vanguard Group, Inc.

4.83%

Geode Capital Management, L.L.C.

2.10%

State Street Investment Management (US)

1.75%

其他

69.99%

股东类型

持股股东

占比

Investment Advisor

16.23%

Corporation

15.51%

Investment Advisor/Hedge Fund

8.08%

Hedge Fund

4.60%

Research Firm

1.99%

Individual Investor

1.28%

Bank and Trust

0.98%

Pension Fund

0.17%

Venture Capital

0.12%

其他

51.03%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

267

14.69M

38.00%

+7.56K

2025Q3

269

14.68M

44.13%

+675.04K

2025Q2

254

13.97M

53.43%

-4.77M

2025Q1

240

18.64M

48.30%

-3.42M

2024Q4

201

17.56M

26.28%

+9.11M

2024Q3

144

8.40M

24.51%

+1.94M

2024Q2

116

6.44M

24.20%

+1.62M

2024Q1

4.82M

22.54%

-2.30M

2023Q4

4.02M

18.98%

-1.52M

2023Q3

5.55M

11.71%

+2.91M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Nippon Shinyaku Co Ltd

7.09M

15.51%

+4.94M

+230.41%

Sep 20, 2024

BlackRock Institutional Trust Company, N.A.

2.73M

5.96%

+34.47K

+1.28%

Jun 30, 2025

The Vanguard Group, Inc.

2.30M

5.02%

+41.09K

+1.82%

Jun 30, 2025

Geode Capital Management, L.L.C.

963.08K

2.11%

+61.70K

+6.85%

Jun 30, 2025

State Street Investment Management (US)

1.47M

3.21%

-376.12K

-20.41%

Jun 30, 2025

Pier Capital, LLC

367.72K

0.8%

+13.54K

+3.82%

Jun 30, 2025

Morgan Stanley & Co. LLC

463.03K

1.01%

-272.07K

-37.01%

Jun 30, 2025

Two Sigma Investments, LP

216.46K

0.47%

+91.50K

+73.23%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Neuroscience and Healthcare ETF

0.36%

Virtus LifeSci Biotech Clinical Trials ETF

0.32%

ALPS Medical Breakthroughs ETF

0.12%

iShares Micro-Cap ETF

0.05%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.02%

ProShares UltraPro Russell2000

0.01%

iShares Russell 2000 Growth ETF

0.01%

iShares Russell 2000 ETF

0.01%

Global X Russell 2000 ETF

0.01%

ProShares Hedge Replication ETF

0.01%

iShares Neuroscience and Healthcare ETF

占比0.36%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.32%

ALPS Medical Breakthroughs ETF

占比0.12%

iShares Micro-Cap ETF

占比0.05%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

占比0.02%

ProShares UltraPro Russell2000

占比0.01%

iShares Russell 2000 Growth ETF

占比0.01%

iShares Russell 2000 ETF

占比0.01%

Global X Russell 2000 ETF

占比0.01%

ProShares Hedge Replication ETF

占比0.01%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Capricor Therapeutics Inc的前五大股东是谁？



Capricor Therapeutics Inc 的前五大股东如下：
Nippon Shinyaku Co Ltd持有股份：7.09M，占总股份比例：15.51%。
BlackRock Institutional Trust Company, N.A.持有股份：2.73M，占总股份比例：5.96%。
The Vanguard Group, Inc.持有股份：2.30M，占总股份比例：5.02%。
Geode Capital Management, L.L.C.持有股份：963.08K，占总股份比例：2.11%。
State Street Investment Management (US)持有股份：1.47M，占总股份比例：3.21%。